Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06976021 | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy(INTROSPECTION) | not yet recruiting | Phase 2 | 60 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 0 | May 16, 2025 | clinicaltrials |
| NCT05795244 | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) | recruiting | Phase 2 | 30 | Yonsei UniversityOTHER |
| 1 |
| May 13, 2025 |
| clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | terminated | Phase 2 | 8 | Baptist Health South FloridaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06942416 | Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | recruiting | Phase 2 | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06705075 | Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE | recruiting | Phase 2 | 80 | Thomas Jefferson UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06916117 | Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC | not yet recruiting | Phase 2 | 30 | RenJi HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06917092 | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer(QLPPEC/GOG-003) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer | terminated | Phase 2 | 4 | Brown UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer(LiDer) | withdrawn | Phase 1 / Phase 2 | 0 | Vall d'Hebron Institute of OncologyOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT06878222 | Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC | recruiting | Phase 2 | 35 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT00513786 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | completed | Phase 2 | 38 | David O'MalleyOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06882447 | A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer(QL1706) | not yet recruiting | Phase 2 | 35 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 28, 2025 | clinicaltrials |
| NCT06786780 | Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids(ECCO) | enrolling by invitation | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04516616 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 85 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06288360 | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06093438 | Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT04380805 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | completed | Phase 2 | 30 | AkesoINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04487587 | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer(COMICE) | active not recruiting | Phase 2 | 79 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04951921 | Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy | completed | Phase 2 | 6 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04275713 | Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC(METOXY-LACC) | completed | Phase 2 | 41 | Oslo University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06353061 | Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer | unknown | Phase 2 | 51 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | enrolling by invitation | Phase 2 / Phase 3 | 510 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03099499 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | terminated | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT06237257 | A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer | unknown | Phase 2 | 56 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745219 | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02035787 | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | completed | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2025source: clinicaltrials